Autolus Therapeutics PLCNASDAQ:AUTL
- LAST PRICE3.4100
- TODAY'S CHANGE (%)-0.0800 (-2.2923%)
- Bid / Lots3.4100/ 19
- Ask / Lots3.4200/ 44
- Open / Previous Close3.5000 / 3.4900
- Day Range
- 52 Week Range
- Volume1,447,111
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AUTL |
|---|---|---|
| 09:32 ET | 1414 | 3.49 |
| 09:34 ET | 200 | 3.46 |
| 09:36 ET | 380 | 3.46 |
| 09:38 ET | 3922 | 3.5 |
| 09:39 ET | 1000 | 3.5 |
| 09:41 ET | 3260 | 3.5 |
| 09:43 ET | 101800 | 3.505 |
| 09:45 ET | 1026 | 3.49 |
| 09:48 ET | 300 | 3.485 |
| 09:50 ET | 23029 | 3.51 |
| 09:52 ET | 500 | 3.5 |
| 09:54 ET | 900 | 3.47 |
| 09:56 ET | 300 | 3.46 |
| 09:57 ET | 5092 | 3.465 |
| 09:59 ET | 4703 | 3.5 |
| 10:01 ET | 1400 | 3.49 |
| 10:03 ET | 400 | 3.49 |
| 10:06 ET | 3800 | 3.495 |
| 10:08 ET | 1800 | 3.495 |
| 10:10 ET | 400 | 3.495 |
| 10:12 ET | 209873 | 3.49 |
| 10:14 ET | 1848 | 3.49 |
| 10:15 ET | 3813 | 3.485 |
| 10:17 ET | 2703 | 3.5 |
| 10:19 ET | 402696 | 3.485 |
| 10:21 ET | 21537 | 3.48 |
| 10:24 ET | 200 | 3.46 |
| 10:28 ET | 2504 | 3.48 |
| 10:30 ET | 2854 | 3.445 |
| 10:32 ET | 1062 | 3.435 |
| 10:33 ET | 1216 | 3.44 |
| 10:35 ET | 55484 | 3.42 |
| 10:37 ET | 4483 | 3.41 |
| 10:39 ET | 3441 | 3.425 |
| 10:44 ET | 200 | 3.415 |
| 10:46 ET | 4596 | 3.41 |
| 10:48 ET | 14192 | 3.44 |
| 10:50 ET | 77862 | 3.49 |
| 10:51 ET | 3800 | 3.495 |
| 10:53 ET | 3761 | 3.51 |
| 10:55 ET | 738 | 3.505 |
| 10:57 ET | 200 | 3.5 |
| 11:00 ET | 3848 | 3.49 |
| 11:02 ET | 200 | 3.47 |
| 11:04 ET | 648 | 3.475 |
| 11:06 ET | 200 | 3.47 |
| 11:08 ET | 3072 | 3.465 |
| 11:09 ET | 1081 | 3.46 |
| 11:11 ET | 4893 | 3.445 |
| 11:13 ET | 948 | 3.445 |
| 11:15 ET | 2207 | 3.43 |
| 11:18 ET | 788 | 3.425 |
| 11:20 ET | 1948 | 3.43 |
| 11:22 ET | 200 | 3.425 |
| 11:24 ET | 884 | 3.42 |
| 11:26 ET | 248 | 3.425 |
| 11:27 ET | 300 | 3.425 |
| 11:29 ET | 400 | 3.425 |
| 11:31 ET | 992 | 3.43 |
| 11:33 ET | 4706 | 3.425 |
| 11:36 ET | 200 | 3.425 |
| 11:38 ET | 216 | 3.425 |
| 11:40 ET | 229 | 3.42 |
| 11:42 ET | 804 | 3.42 |
| 11:44 ET | 12225 | 3.41 |
| 11:45 ET | 882 | 3.41 |
| 11:47 ET | 12595 | 3.405 |
| 11:49 ET | 700 | 3.405 |
| 11:51 ET | 1921 | 3.4 |
| 11:54 ET | 300 | 3.39 |
| 11:56 ET | 935 | 3.39 |
| 11:58 ET | 1000 | 3.385 |
| 12:00 ET | 4416 | 3.37 |
| 12:02 ET | 200 | 3.36 |
| 12:03 ET | 788 | 3.35 |
| 12:05 ET | 1480 | 3.355 |
| 12:07 ET | 1806 | 3.345 |
| 12:09 ET | 750 | 3.345 |
| 12:12 ET | 21494 | 3.32 |
| 12:14 ET | 5329 | 3.33 |
| 12:16 ET | 1200 | 3.33 |
| 12:18 ET | 3392 | 3.34 |
| 12:20 ET | 200 | 3.34 |
| 12:21 ET | 1180 | 3.35 |
| 12:23 ET | 532 | 3.34 |
| 12:25 ET | 600 | 3.335 |
| 12:27 ET | 670 | 3.33 |
| 12:30 ET | 519 | 3.325 |
| 12:32 ET | 1980 | 3.31 |
| 12:34 ET | 1026 | 3.305 |
| 12:36 ET | 1149 | 3.3 |
| 12:38 ET | 2500 | 3.31 |
| 12:39 ET | 2600 | 3.31 |
| 12:41 ET | 300 | 3.305 |
| 12:43 ET | 200 | 3.3 |
| 12:45 ET | 900 | 3.3 |
| 12:48 ET | 300 | 3.3 |
| 12:50 ET | 400 | 3.305 |
| 12:52 ET | 3762 | 3.315 |
| 12:54 ET | 100 | 3.31 |
| 12:56 ET | 1673 | 3.32 |
| 12:57 ET | 4348 | 3.315 |
| 12:59 ET | 1138 | 3.325 |
| 01:01 ET | 100 | 3.32 |
| 01:03 ET | 2743 | 3.325 |
| 01:06 ET | 300 | 3.32 |
| 01:08 ET | 4368 | 3.31 |
| 01:10 ET | 2467 | 3.31 |
| 01:12 ET | 400 | 3.3 |
| 01:14 ET | 1200 | 3.3 |
| 01:15 ET | 8757 | 3.3 |
| 01:17 ET | 400 | 3.295 |
| 01:19 ET | 2518 | 3.305 |
| 01:21 ET | 100 | 3.3 |
| 01:24 ET | 400 | 3.3 |
| 01:26 ET | 469 | 3.3 |
| 01:28 ET | 1050 | 3.295 |
| 01:30 ET | 3013 | 3.295 |
| 01:32 ET | 5100 | 3.295 |
| 01:33 ET | 2448 | 3.2929 |
| 01:35 ET | 569 | 3.29 |
| 01:37 ET | 288 | 3.29 |
| 01:39 ET | 769 | 3.29 |
| 01:42 ET | 1695 | 3.29 |
| 01:44 ET | 6599 | 3.305 |
| 01:46 ET | 300 | 3.3 |
| 01:48 ET | 300 | 3.3 |
| 01:50 ET | 1807 | 3.3 |
| 01:51 ET | 200 | 3.3 |
| 01:53 ET | 2830 | 3.31 |
| 01:55 ET | 800 | 3.3012 |
| 01:57 ET | 800 | 3.3 |
| 02:00 ET | 3465 | 3.31 |
| 02:02 ET | 1990 | 3.31 |
| 02:04 ET | 200 | 3.3 |
| 02:06 ET | 8168 | 3.315 |
| 02:08 ET | 2400 | 3.305 |
| 02:09 ET | 2800 | 3.32 |
| 02:11 ET | 400 | 3.31 |
| 02:13 ET | 400 | 3.315 |
| 02:15 ET | 3577 | 3.33 |
| 02:18 ET | 300 | 3.325 |
| 02:20 ET | 10125 | 3.34 |
| 02:22 ET | 1720 | 3.345 |
| 02:24 ET | 400 | 3.345 |
| 02:26 ET | 300 | 3.345 |
| 02:27 ET | 600 | 3.345 |
| 02:29 ET | 700 | 3.345 |
| 02:31 ET | 701 | 3.34 |
| 02:33 ET | 5599 | 3.345 |
| 02:36 ET | 963 | 3.34 |
| 02:38 ET | 10033 | 3.355 |
| 02:40 ET | 300 | 3.35 |
| 02:42 ET | 4626 | 3.34 |
| 02:44 ET | 13949 | 3.35 |
| 02:45 ET | 1100 | 3.35 |
| 02:47 ET | 500 | 3.35 |
| 02:49 ET | 400 | 3.35 |
| 02:51 ET | 8737 | 3.365 |
| 02:54 ET | 600 | 3.365 |
| 02:56 ET | 200 | 3.365 |
| 02:58 ET | 300 | 3.36 |
| 03:00 ET | 1238 | 3.365 |
| 03:02 ET | 51367 | 3.385 |
| 03:03 ET | 5284 | 3.39 |
| 03:05 ET | 1980 | 3.39 |
| 03:07 ET | 1600 | 3.395 |
| 03:09 ET | 4527 | 3.398 |
| 03:12 ET | 1490 | 3.39 |
| 03:14 ET | 1210 | 3.39 |
| 03:16 ET | 1400 | 3.39 |
| 03:18 ET | 4763 | 3.4 |
| 03:20 ET | 400 | 3.4 |
| 03:21 ET | 500 | 3.405 |
| 03:23 ET | 1269 | 3.405 |
| 03:25 ET | 1569 | 3.4 |
| 03:27 ET | 1200 | 3.4 |
| 03:30 ET | 3285 | 3.395 |
| 03:32 ET | 1469 | 3.395 |
| 03:34 ET | 1681 | 3.395 |
| 03:36 ET | 4739 | 3.395 |
| 03:38 ET | 3567 | 3.395 |
| 03:39 ET | 11516 | 3.415 |
| 03:41 ET | 1400 | 3.415 |
| 03:43 ET | 2490 | 3.415 |
| 03:45 ET | 4244 | 3.41 |
| 03:48 ET | 5464 | 3.405 |
| 03:50 ET | 6358 | 3.405 |
| 03:52 ET | 7599 | 3.415 |
| 03:54 ET | 2500 | 3.41 |
Jun 17, 2024
DJ Autolus Therapeutics Price Target Maintained With a $9.00/Share by Needham, from 6:02AM ET on Monday Jun 17, 2024 by Dow Jones
6:02AM ET on Monday Jun 17, 2024 by Dow Jones
Jun 14, 2024
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress, from 7:00AM ET on Friday Jun 14, 2024 by Dow Jones
7:00AM ET on Friday Jun 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Autolus Therapeutics PLC | 928.5M | -2.8x | --- |
Tyra Biosciences Inc | 891.6M | -10.1x | --- |
Cullinan Therapeutics Inc | 967.1M | -5.1x | --- |
ARS Pharmaceuticals Inc | 880.8M | -17.6x | --- |
Pharvaris NV | 916.9M | -6.5x | --- |
Centessa Pharmaceuticals PLC | 969.9M | -6.1x | --- |
Company Information
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Contact Information
- Headquarters
- The Mediaworks, 191 Wood LaneLONDON, United Kingdom W12 7FP
- Phone
- 203-829-6230
- Fax
- ---
Executives
- Chairman of the Board
- Michael Bonney
- Chief Executive Officer, Executive Director
- Christian Itin
- Founder, Senior Vice President, Chief Scientific Officer
- Martin Pule
- Chief Financial Officer, Senior Vice President
- Lucinda Crabtree
- Chief Operating Officer, Senior Vice President
- Christopher Vann
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $928.5M |
|---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 266.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.11 |
EPS | $-1.21 |
Book Value | --- |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 88.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,670.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
